Acute Pain Clinical Trial
— KETOAPPOfficial title:
Intravenous Ketorolac Vs. Morphine In Children Presenting With Acute Abdominal Pain And/or Suspected Appendicitis: A Multi-centre Non-Inferiority Randomized Controlled Trial
NCT number | NCT06160778 |
Other study ID # | 23-0952 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | May 14, 2024 |
Est. completion date | December 2029 |
Appendicitis is a common condition in children 6-17 years of age, and the top reason for emergency surgery in Canada. Children with appendicitis can have very bad pain in their belly. Children often need pain medications given to them through a needle in their arm called an intravenous (IV). The most common IV pain medication is a type of opioid called morphine. We know that opioids work well to improve pain, but there are risks and side effects when taking them. There are non-opioid medications that doctors can give to patients, like ketorolac. Ketorolac helps decrease inflammation and pain and has fewer side effects when a patient takes it for a short period of time. Our past and present overuse of opioids, driven by an unproven assumption that opioids work best for pain, resulted in an Opioid Crisis and doctors are now looking for alternatives. To do this, we need to prove that there are other options to treat children's pain that are just as good as opioids, with less side effects. The goal of our study is to discover if school aged children who arrive at the emergency department with belly pain, improve just as much with ketorolac as they do with morphine. To answer this question, we will need a very large number of patients in a study that includes several hospitals across Canada. With a flip of a coin, each participant will either get a single dose of morphine or a single dose of ketorolac. To make sure that our pain assessment is impartial, no one will know which medicine the child received except the pharmacist who prepared the medicine.
Status | Recruiting |
Enrollment | 495 |
Est. completion date | December 2029 |
Est. primary completion date | January 2029 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 17 Years |
Eligibility | Inclusion Criteria: 1. Age 6 to 17 years 2. Abdominal pain =5 days duration 3. Acute abdominal pain that is being investigated (suspected) by the clinical team for appendicitis 4. Patient with IV cannula in situ or ordered 5. Currently experiencing moderate to severe abdominal pain at rest or with movement: self-reported pain score =5 using the verbal Numerical Rating Scale Exclusion Criteria: 1. Previous enrollment in the trial 2. NSAID use within 3 hours and/or opioid use within 1 to 2 hours (1 hour post-IV or intra-nasal fentanyl and 2 hours post IV morphine). 3. Children who need immediate resuscitation, are hemodynamically unstable as deemed by the clinical team or have a Canadian Triage Assessment Score of 1 4. Significant caregiver and/or child cognitive impairment precluding the ability to complete study questions. 5. Chronic pain requiring daily analgesic use: confounding as response to analgesics maybe altered. 6. History of severe undiagnosed gastrointestinal bleeding requiring medical intervention, peptic or duodenal ulcer disease or inflammatory bowel disease, coagulation disorders, prior cerebrovascular bleeding, known arterio-vascular malformations. History of minor gastrointestinal bleeding from conditions such as resolved fissures, polyps or allergic colitis will not exclude patients from participating. 7. History of chronic and active interstitial kidney disease 8. History of chronic and active hepatocellular disease: ketorolac is metabolized by the liver. 9. Known or suspected pregnancy at the time of enrollment or breastfeeding females 10. Known hypersensitivity to NSAIDs or opioids. 11. Absence of a parent/guardian for children who are <16 years of age if they are not a mature minor. 12. Inability to obtain consent due to a language barrier and the absence of language translator in person or by a phone translation service available in the ED. |
Country | Name | City | State |
---|---|---|---|
Canada | Alberta Children's Hospital Emergency Department | Calgary | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Calgary | Canadian Institutes of Health Research (CIHR) |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Appendix visualization on ultrasound | proportion of participants who had the appendix visualized on ultrasound | post-randomization and up to 8 hours post-intervention. | |
Primary | Pain relief as measured on the verbal numerical rating scale | Between group mean differences in pain as measured on an 11-point verbal Numerical Rating Scale (0 is no pain and 10 is worst pain ever) | 60 minutes post drug administration | |
Secondary | Pain relief as measured on the verbal numerical rating scale | Between group mean differences in pain as measured on an 11-point verbal | 30 minutes post drug administration | |
Secondary | Pain relief as measured on the verbal numerical rating scale | Between group mean differences in pain as measured on an 11-point verbal | 90 minutes post drug administration | |
Secondary | Pain relief as measured on the verbal numerical rating scale | Between group mean differences in pain as measured on an 11-point verbal | 120 minutes post drug administration | |
Secondary | Pain relief as measured on the verbal numerical rating scale | Between group mean differences in pain as measured on an 11-point verbal | 6 hours post drug administration | |
Secondary | Pain relief as measured on the verbal numerical rating scale during the ultrasound diagnostic | score from 0-10 on verbal numerical rating scale | up to 6 hours post drug administration | |
Secondary | Proportion who achieve the minimal important difference for pain relief | Proportion of participants who achieves the 2-point verbal Numerical Rating Scale minimal important difference pain score reduction | 60 minutes post drug administration | |
Secondary | Proportion who achieve the minimal important difference for pain relief | Proportion of participants who achieves the 2-point verbal Numerical Rating Scale minimal important difference pain score reduction | 120 minutes post drug administration | |
Secondary | Change in baseline pain category | Proportion of participants who change the severity of their baseline pain category. Pain categories on the verbal numerical rating scale as follows: mild = 0 to 4, moderate = 5 to 7, severe >7) | 30 minutes post drug administration | |
Secondary | Change in baseline pain category | Proportion of participants who change the severity of their baseline pain category. Pain categories on the verbal numerical rating scale as follows: mild = 0 to 4, moderate = 5 to 7, severe >7) | 60 minutes post drug administration | |
Secondary | Change in baseline pain category | Proportion of participants who change the severity of their baseline pain category. Pain categories on the verbal numerical rating scale as follows: mild = 0 to 4, moderate = 5 to 7, severe >7) | 90 minutes post drug administration | |
Secondary | Change in baseline pain category | Proportion of participants who change the severity of their baseline pain category. Pain categories on the verbal numerical rating scale as follows: mild = 0 to 4, moderate = 5 to 7, severe >7) | 120 minutes post drug administration | |
Secondary | Change in baseline pain category | Proportion of participants who change the severity of their baseline pain category. Pain categories on the verbal numerical rating scale as follows: mild = 0 to 4, moderate = 5 to 7, severe >7) | 6 hours post drug administration | |
Secondary | Time to effective analgesia | Duration of time from time of drug administration to time at which a verbal Numerical Rating Scale =3 is achieved. | up to 6 hours post drug administration | |
Secondary | Additional analgesia requirment | Proportion of participants requiring any additional analgesia in each trial arm | up to 6 hours post drug administration | |
Secondary | Total opioids administered | total morphine-equivalent mg/kg administered for all trial participants | up to 8 hours post drug administration | |
Secondary | Ramsay sedation score | Assessment of sedation levels post drug administration; score is 1-6 (1 is alert, 6 is not responsive) | 30 minutes post drug administration | |
Secondary | Ramsay sedation score | Assessment of sedation levels post drug administration; score is 1-6 (1 is alert, 6 is not responsive) | 60 minutes post drug administration | |
Secondary | Ramsay sedation score | Assessment of sedation levels post drug administration; score is 1-6 (1 is alert, 6 is not responsive) | 90 minutes post drug administration | |
Secondary | Ramsay sedation score | Assessment of sedation levels post drug administration; score is 1-6 (1 is alert, 6 is not responsive) | 120 minutes post drug administration | |
Secondary | Adverse events per participant | Frequency of specific adverse event occurrence per participant enrolled | up to 6 hours post drug administration | |
Secondary | Frequency of each specific adverse event | Frequency of each specific adverse event occurrence | up to 6 hours post drug administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04484610 -
Appropriate Opioid Quantities for Acute Pain - Pharmacist Study
|
Phase 4 | |
Recruiting |
NCT05054179 -
Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain
|
Phase 2/Phase 3 | |
Completed |
NCT04548635 -
VR for Burn Dressing Changes at Home
|
Phase 2/Phase 3 | |
Recruiting |
NCT05370404 -
Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain:
|
N/A | |
Completed |
NCT06054945 -
Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
|
||
Completed |
NCT03825549 -
A Randomized Trial of Behavioral Economic Approaches to Reduce Unnecessary Opioid Prescribing
|
N/A | |
Completed |
NCT05995912 -
Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain
|
Phase 2 | |
Recruiting |
NCT05589246 -
Regional Analgesia in Combination With Cryoanalgesia to Prevent Acute Pain Following Nuss Procedure
|
N/A | |
Recruiting |
NCT05572190 -
Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects
|
Phase 1 | |
Terminated |
NCT04716413 -
Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment
|
Phase 4 | |
Active, not recruiting |
NCT03537573 -
Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care
|
N/A | |
Not yet recruiting |
NCT06317844 -
Examination of Psychological and Physiological Pathways Linking Gratitude and Pain
|
N/A | |
Withdrawn |
NCT02957097 -
Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures
|
Phase 4 | |
Terminated |
NCT02599870 -
Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures
|
N/A | |
Completed |
NCT02565342 -
Interscalene Brachial Plexus Block to Treat Pain After Clavicular Surgery
|
Phase 4 | |
Completed |
NCT02984098 -
40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose
|
Phase 4 | |
Completed |
NCT02380989 -
Integrative Ayurveda Healing Relieves Minor Sports Injury Pain
|
Phase 2 | |
Completed |
NCT03107338 -
Preventive Treatment of Pain After Dental Implant Surgery
|
Phase 4 | |
Completed |
NCT02489630 -
Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department
|
Phase 4 | |
Completed |
NCT02817477 -
Intranasal Ketamine for Acute Traumatic Pain
|
Phase 4 |